Elanco Animal Health (ELAN) Reiterated at Buy by Stifel on Befrena Adoption Potential

Stifel analyst Jonathan Block reiterated a Buy rating and $33.00 price target on Elanco Animal Health (NYSE: ELAN).

The analyst commented, "For Elanco, Befrena is the standout from the survey. Over 50% of current Cytopoint users expect to adopt Befrena over the NTM, with the majority (~70%) showing a willingness to switch current Cytopoint users. We believe Befrena will contribute 100+ bps to organic growth in 2027 and again in 2028. For Zenrelia, U.S. share gains are moderating (due to Numelvi traction), but in-line with our WW Atopic Dermatitis JAK market model. In 2027, the primary top-line drivers for Elanco are likely Befrena, O-U.S. Zenrelia, O-U.S. Credelio Quattro, and to a lesser extent, U.S. Zenrelia. Reiterate Buy."

For an analyst ratings summary and ratings history on Elanco Animal Health click here. For more ratings news on Elanco Animal Health click here.

Shares of Elanco Animal Health closed at $22.74 yesterday.

You May Also Be Interested In

• Kotak Upgrades Indusind Bank Ltd (IIB:IN) to Reduce (3)
• Kotak Upgrades Shriram Finance Ltd (SHFL:IN) to Buy (1)
• Dr. Reddy\'s Laboratories (DRRD:IN) (RDY) PT Raised to INR1,220 at Kotak